| Ytd | -9.78% | |
| 1y | -17.60% |
| Open | 1.64 | Prev Close | 1.63 | Low | 1.59 | High | 1.67 | Mkt Cap | 299.23M |
| Vol | 402.75K | Avg Vol | 2.20M | EPS | -1.33 | P/E | -1.21 | Forward P/E | -1.01 |
| Beta | 2.74 | Short Ratio | 4.59 | Inst. Own | 72.13% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 1.68 | 200-d Avg | 2.19 | 1yr Est | 11.77 |
RBC Capital analyst Brian Abrahams maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform
US stock futures rise, Nasdaq 100 up 1%. Datadog (DDOG) downgraded, pre-market trading. Other declin
Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics
Health officials explored restricting specific antidepressants among SSRI drugs-sources
U.S. stock futures mixed with Dow futures down 0.1%. Domino's Pizza misses earnings expectations